The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
GnRH antagonists in ovarian stimulation for IVF
Abstract
The present review describes, on the basis of the currently available evidence, the consensus reached by a group of experts on the use of gonadotropin-releasing hormone (GnRH) antagonists in ovarian stimulation for IVF. The single or multiple low-dose administration of GnRH antagonist during the late-follicular phase effectively prevents a premature rise in serum luteinizing hormone (LH) levels in most women. Although controversy remains, most comparative studies suggest a slight, not significant reduction in the probability of pregnancy after IVF using GnRH antagonist versus GnRH agonist co-treatment. Published meta-analyses suggest that this slight difference in pregnancy rates is not attributed to chance. Further studies applying varying treatment regimens and outcome measures are required. Data are not in favour of a need to modify the starting dose of gonadotropins. Data are not in favour of increasing gonadotropin dose at GnRH antagonist initiation. The addition of LH from the initiation of ovarian stimulation or from GnRH antagonist administration does not appear to be necessary. Replacement of human chorionic gonadotropin (HCG) by GnRH agonist for triggering final oocyte maturation is associated with a lower probability of pregnancy. The optimal timing for HCG administration needs to be explored further. GnRH antagonist initiation on day 6 of stimulation appears to be superior to flexible initiation by a follicle of 14-16 mm, although earlier GnRH antagonist administration is worth further evaluation. Luteal phase supplementation in GnRH antagonist protocols remains mandatory in IVF. Effects of GnRH antagonist co-treatment on the incidence of ovarian hyperstimulation syndrome remains uncertain, although a trend is present in favour of the GnRH antagonists. The role of GnRH antagonists in ovarian stimulation for IVF appears to be promising, although many questions regarding preferred dose regimens and effects on clinical outcomes remain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Westergaard, L. G. (2000) · Human Reproduction · doi:10.1093/humrep/15.5.1003 · Cited by 301
Duijkers, I. J., Klipping, C., Willemsen, W. N., Krone, D., Schneider, E., Niebch, G., & Hermann, R. (1998) · Human Reproduction · doi:10.1093/humrep/13.9.2392 · Cited by 114
Cited by
Gonadotropin-Releasing Hormone and Its Analogues
Kovacs, P. (2020) · Textbook of Assisted Reproduction · doi:10.1007/978-981-15-2377-9_8 · Cited by 422
Effective method for emergency fertility preservation: random-start controlled ovarian stimulation
Cakmak, H., Katz, A., Cedars, M. I., & Rosen, M. P. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.07.1992 · Cited by 332
Kolibianakis, E. M., Collins, J., Tarlatzis, B. C., Devroey, P., Diedrich, K., & Griesinger, G. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml038 · Cited by 306
Self-citation
Metadata
- Authors
- Tarlatzis, B. C.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03-24
- Volume
- 12
- Issue
- 4
- Pages
- 333-340
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2133328152
- Cited by
- 235
- References
- 2
- FWCI
- 18.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GnRH antagonists in ovarian stimulation for IVF. https://app.cochat.ai/papers/10.1093/humupd/dml001
- The paper
- Tarlatzis, B. C. (2006). GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update. https://doi.org/10.1093/humupd/dml001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.